Therapy of coronary vasoconstriction in patients with coronary artery disease.
Patients with obstructive coronary artery disease and stable, exertional angina respond to the alpha adrenergic stimulus of the cold pressor test with an inappropriate increase in coronary vascular resistance. The clinical significance of this abnormal response and its possible role in the pathogenesis of ischemic heart disease are discussed. Comparison of the anti-anginal agents currently in use of undergoing investigation suggests that the calcium antagonists may be the most effective therapy for coronary vasoconstriction. Nifedipine, 10 mg buccally, successfully prevented the increase in coronary vascular resistance during the cold pressor test in 10 of 10 patients, whereas the response in placebo-treated patients was unaltered. This dose of nifedipine was without effect on systemic hemodynamics or myocardial oxygen consumption, suggesting a selective antivasoconstrictor effect on the coronary vasculature.
D000787:Angina Pectoris / Q000188:drug therapy / Q000503:physiopathology; D003080:Cold Temperature; D003327:Coronary Disease / Q000188:drug therapy / Q000503:physiopathology*; D003331:Coronary Vessels / Q000503:physiopathology*; D005080:Exercise Test; D006352:Heart Ventricles / Q000503:physiopathology; D006801:Humans; D009206:Myocardium / Q000378:metabolism; D009543:Nifedipine / Q000627:therapeutic use; D005996:Nitroglycerin / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D011311:Pressoreceptors / Q000503:physiopathology; D011433:Propranolol / Q000627:therapeutic use; D012039:Regional Blood Flow; D014661:Vasoconstriction
D011433:Propranolol; D005996:Nitroglycerin; D009543:Nifedipine; D010646:Phentolamine